Dupilumab Improves AD in Kids With and Without Type 2 Comorbidities
Dupilumab (Dupixent, Sanofi & Regeneron) works well in children with atopic dermatitis (AD) regardless of whether they have any type 2 co-morbid conditions, according to a new study in Advances in Therapy. For the LIBERTY AD PRESCHOOL part B study, investigators evaluated children aged 6 months to 5 years with moderate-to-severe AD who had been treated with […]